Enliven Therapeutics (ELVN) Cash from Operations (2019 - 2026)

Enliven Therapeutics has disclosed Cash from Operations across 8 years of filings, most recently posting 19291000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 19291000.0, up 20.04% year-over-year; the trailing twelve-month figure through Mar 2026 was 65465000.0 (up 11.48% YoY), and the FY2025 annual result was 70301000.0, up 3.95% from the prior year.
• Cash from Operations came in at 19291000.0 for Q1 2026 at Enliven Therapeutics, down from 15838000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 6447000.0 in Q3 2022 to a low of 24127000.0 in Q1 2025.
• The 5-year median for Cash from Operations is 15838000.0 (2025), against an average of 15066470.59.
• Across the five-year window, Cash from Operations surged 40.86% in 2022 and sank 146.53% in 2023, its largest moves.
• Enliven Therapeutics' Cash from Operations stood at 8145000.0 in 2022, then slumped by 53.25% to 12482000.0 in 2023, then tumbled by 37.82% to 17203000.0 in 2024, then increased by 7.93% to 15838000.0 in 2025, then decreased by 21.8% to 19291000.0 in 2026.
• The last three Cash from Operations figures came in at 19291000.0 (Q1 2026), 15838000.0 (Q4 2025), and 13279000.0 (Q3 2025), per Business Quant data.